98%
921
2 minutes
20
Introduction: Immune checkpoint inhibitors (ICIs) have become key therapies for various malignancies by restoring antitumor immunity. However, they may trigger immune-related adverse events (irAEs), including neurological irAEs (n-irAEs), which, though rare, can be severe. Among these, neuromuscular disorders affecting peripheral nerves, the neuromuscular junction (NMJ), and muscle are the most frequent and carry the highest mortality risk, warranting prompt recognition.
Objective: To describe the clinical and electrodiagnostic features of ICI-related neuromuscular disorders in 38 patients.
Methods: We retrospectively analyzed patients treated with ICIs referred for electrodiagnostic evaluation due to suspected n-irAEs. Patients were categorized into two phenotypes: (1) ir-Neuropathies (cranial/peripheral neuropathies, radiculopathies) and (2) ir-MG/myositis (myasthenia gravis and/or myositis). Studies included motor/sensory conduction, F-waves, needle EMG, and, when indicated, single-fiber EMG, repetitive stimulation, and evoked potentials.
Results: Of 38 patients, 27 (71%) had ir-MG/myositis and 11 (29%) ir-Neuropathies. Myositis with spontaneous activity was the most frequent ir-MG/myositis pattern. In ir-Neuropathies, acute sensory-motor demyelinating polyradiculoneuropathy predominated.
Conclusions: Myositis is the most common ir-MG/myositis pattern, while demyelinating polyradiculoneuropathy is typical of ir-Neuropathies. NMJ dysfunction often coexists with myositis and may be missed electrophysiologically.
Significance: Electrodiagnosis is essential for early detection and management of ICI-related neuromuscular complications.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.clinph.2025.2110989 | DOI Listing |
J Oncol Pharm Pract
September 2025
Department of Research & Development, Squad Medicine and Research (SMR), Amadalavalasa, Andhra Pradesh, India.
Cancer vaccines represent a transformative shift in oncology, aiming to prevent malignancies or treat established cancers by training the immune system to recognize tumor-specific or tumor-associated antigens. This review explores the diverse platforms and mechanisms supporting cancer vaccines, ranging from prophylactic vaccines such as HPV and hepatitis B vaccines that have significantly reduced virus-related cancers to therapeutic vaccines like Sipuleucel-T and T-VEC that extend survival in prostate cancer and melanoma. Vaccine types are classified, and delivery platforms including mRNA, peptide, dendritic cell and viral vector-based approaches are examined alongside pivotal clinical trial outcomes.
View Article and Find Full Text PDFCancer Immunol Res
September 2025
University of Pennsylvania, Philadelphia, PA, United States.
Pancreatic ductal adenocarcinoma (PDA) is defined by a myeloid-enriched microenvironment and has shown remarkable resistance to immune checkpoint blockade (e.g., PD-1 and CTLA-4).
View Article and Find Full Text PDFACS Nano
September 2025
School of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China.
Although traditional immunogenic cell death (ICD) inducers generate vaccines (ISV) to potentiate antiprogrammed cell death ligand 1 (anti-PDL1) antibodies therapy, their efficacy remains limited. This limitation may be attributed to the physical barrier created by extracellular matrix (ECM) and immunosuppressive metabolic barrier mediated by adenosine. Here, we report an oncolytic polymer (OP), a well-designed ε-polylysine derivative with ICD-inducing capacity, which can simultaneously facilitate the release of endogenous ECM-degrading enzyme, Cathepsin B.
View Article and Find Full Text PDFAsia Pac J Oncol Nurs
December 2025
Department of Prevention Management, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Objective: To identify and evaluate the methodological quality and psychometric properties of Patient-reported outcome measures (PROMs) for symptom assessment in patients with cancer undergoing immunotherapy.
Methods: A systematic search was performed in PubMed, Scopus, Cochrane Library, Web of Science, Embase, CINAHL, CNKI, WanFang, Vip, and SinoMed from their inception to February 10, 2025. Eligibility criteria required studies to focus on the development or validation of a PROM for symptom assessment in adult patients with cancer undergoing immunotherapy, and to report on at least one psychometric property.
Front Oncol
August 2025
Hunan Cancer Hospital, The Affiliated Cancer Hospital, Xiangya School of Medicine, Central South University, Changsha, Hunan, China.
Tislelizumab, an anti-PD-1 monoclonal antibody, is associated with immune-related hepatitis in 1.8% of cases, but reports of acute liver failure (ALF) remain exceedingly rare. We present a case of fulminant hepatitis and ALF following Tislelizumab therapy in a 55-year-old woman with locally advanced cervical adenocarcinoma.
View Article and Find Full Text PDF